Kimberly Drenser

Dr. Kimberly Drenser


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Ophthalmology
Verified
Journal Article
Closed access
WDWendy A. Dailey
Wendy A. Dailey
WGWojciech Gryc
Wojciech Gryc
PGPooja G. Garg
Pooja G. Garg
KDKimberly Drenser
Kimberly Drenser

1 January 2018 in Asia-Pacific Journal of Ophthalmology
Verified
Journal Article
Open access
PRPrethy Rao
Prethy Rao
VDVaidehi S. Dedania
Vaidehi S. Dedania
KDKimberly Drenser
Kimberly Drenser
The Asia-Pacific Journal of Ophthalmology (APJO) is the official publication of the Asia-Pacific Academy of Ophthalmology. The APJO positions itself as a first-class bimonthly (6 issues per year) peer-viewed e-journal representative of ophthalmic and visual science developments in the Asia-Pacific region. The APJO welcomes the submission of original, previously unpublished manuscripts which describe clinical investigations, clinical observations and clinically relevant laboratory investigations.

5 November 2023 in Cells
Verified
Journal Article
Open access
PDF file
VLVincent Le
Vincent Le
GAGabrielle Abdelmessih
Gabrielle Abdelmessih
WDWendy Dailey
Wendy Dailey
CPCecille Pinnock
Cecille Pinnock
VJVictoria Jobczyk
Victoria Jobczyk
KMKenneth Mitton
Kenneth Mitton
Familial Exudative Vitreoretinopathy (FEVR), Norrie disease, and persistent fetal vascular syndrome (PFVS) are extremely rare retinopathies that are clinically distinct but are unified by abnormal retinal endothelial cell function, and subsequent irregular retinal vascular development and/or aberrant inner blood-retinal-barrier (iBRB) function. The early angiogenesis of the retina and its iBRB is a delicate process that is mediated by the canonical Norrin Wnt-signaling pathway in retinal endothelial cells. Pathogenic variants in genes that play key roles within this pathway, such as NDP, FZD4, TSPAN12, and LRP5, have been associated with the incidence of these retinal diseases. Recent efforts to further elucidate the etiology of these conditions have not only highlighted their multigenic nature but have also resulted in the discovery of pathological variants in additional genes such as CTNNB1, KIF11, and ZNF408, some of which operate outside of the Norrin Wnt-signaling pathway. Recent discoveries of FEVR-linked variants in two other Catenin genes (CTNND1, CTNNA1) and the Endoplasmic Reticulum Membrane Complex Subunit-1 gene (EMC1) suggest that we will continue to find additional genes that impact the neural retinal vasculature, especially in multi-syndromic conditions. The goal of this review is to briefly highlight the current understanding of the roles of their encoded proteins in retinal endothelial cells to understand the essential functional mechanisms that can be altered to cause these very rare pediatric retinal vascular diseases.

11 March 2022 in Genes
Verified
Journal Article
Open access
PDF file
ACAmanda Petrelli Cicerone
Amanda Petrelli Cicerone
WDWendy Dailey
Wendy Dailey
MSMichael Sun
Michael Sun
ASAndrew Santos
Andrew Santos
DJDaeun Jeong
Daeun Jeong
KMKenneth Mitton
Kenneth Mitton
While Inherited Retinal Diseases (IRDs) are typically considered rare diseases, Familial Exudative Vitreo-Retinopathy (FEVR) and Norrie Disease (ND) are more rare than retinitis pigmentosa. We wanted to determine if multigenic protein-altering variants are common in FEVR subjects within a set of FEVR-related genes. The potential occurrence of protein-altering variants in two different genes has been documented in a very small percentage of patients, but potential multigenic contributions to FEVR remain unclear. Genes involved in these orphan pediatric retinal diseases are not universally included in available IRD targeted-sequencing panels, and cost is also a factor limiting multigenic-sequence-based testing for these rare conditions. To provide an accurate solution at lower cost, we developed a targeted-sequencing protocol that includes seven genes involved in Familial Exudative Vitreo-Retinopathy (FEVR) and Norrie disease. Seventy-six DNA samples from persons refered to clinic with possible FEVR and some close relatives were sequenced using a novel Oakland-ERI orphan pediatric retinal disease panel (version 2) providing 900 times average read coverage. The seven genes involved in FEVR/ND were: NDP (ChrX), CTNNB1 (Chr3); TSPAN12 (Chr7); KIF11 (Chr10), FZD4 (Chr11), LRP5 (Chr11), ZNF408 (Chr11). A total of 33 variants were found that alter protein sequence, with the following relative distribution: LRP5 13/33 (40%), FZD4 9/33 (27%), ZNF408 6/33 (18%), (KIF11 3/33 (9%), NDP 1/33 (3%), CTNNB1 1/33 (3%). Most protein-altering variants, 85%, were found in three genes: FZD4, LRP5, and ZNF408. Four previously known pathogenic variants were detected in five families and two unrelated individuals. Two novel, likely pathogenic variants were detected in one family (FZD4: Cys450ter), and a likely pathogenic frame shift termination variant was detected in one unrelated individual (LRP5: Ala919CysfsTer67). The average number of genes with protein-altering variants was greater in subjects with confirmed FEVR (1.46, n = 30) compared to subjects confirmed unaffected by FEVR (0.95, n = 20), (p = 0.009). Thirty-four percent of persons sequenced had digenic and trigenic protein-altering variants within this set of FEVR genes, which was much greater than expected in the general population (3.6%), as derived from GnomAD data. While the potential contributions to FEVR are not known for most of the variants in a multigenic context, the high multigenic frequency suggests that potential multigenic contributions to FEVR severity warrant future investigation. The targeted-sequencing format developed will support such exploration by reducing the testing cost to $250 (US) for seven genes and facilitating greater access to genetic testing for families with this very rare inherited retinal disease.

18 June 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HPHemang K. Pandya
Hemang K. Pandya
LFLisa J. Faia
Lisa J. Faia
JRJoshua Robinson
Joshua Robinson
KDKimberly Drenser
Kimberly Drenser
Purpose. To report anatomic outcomes after early and confluent laser photocoagulation of the entire avascular retina, including areas in close proximity to the fovea, in patients with APROP. We aspire to demonstrate fundoscopic evidence of transverse growth and macular development following laser treatment in APROP.Methods. Retrospective review of 6 eyes with APROP that underwent confluent laser photocoagulation of the entire avascular retina. Photographic fundoscopic imaging was performed using the RetCam to compare outcomes after treatment.Results. Mean birth weight and gestational age were 704.8 g and 24.33 weeks, respectively. There were 2 females and 1 male. The average time to laser was 9.3 weeks after birth, with the mean postmenstrual age of 34 weeks. Two eyes had zone 1 and 4 eyes had posterior zone 2 disease. Three eyes developed 4A detachments, which were successfully treated. All 6 eyes experienced transverse growth, with expansion of the posterior pole and anterior displacement of the laser treatment.Conclusion. Confluent photocoagulation of the entire avascular retina, regardless of foveal proximity, should be the mainstay for treating APROP. Examination should be conducted within 5–10 days to examine areas previously hidden by neovascularization to ensure prudent therapy. Macular development involves both transverse and anterior-posterior growth.

1 May 2020 in Current Opinion in Ophthalmology
Verified
Journal Article
Closed access
EWEdward H. Wood
Edward H. Wood
EKEdward Korot
Edward Korot
PSPhilip P. Storey
Philip P. Storey
SMStephanie Muscat
Stephanie Muscat
GWGeorge A. Williams
George A. Williams
KDKimberly Drenser
Kimberly Drenser
Purpose of review: The aim of this article is to review and discuss the history, current state, and future implications of promising biomedical offerings in the field of retina. Recent findings: The technologies discussed are some of the more recent promising biomedical developments within the field of retina. There is a US Food and Drug Administration-approved gene therapy product and artificial intelligence device for retina, with many other offerings in the pipeline. Summary: Signaling pathway therapies, genetic therapies, mitochondrial therapies, and artificial intelligence have shaped retina care as we know it and are poised to further impact the future of retina care. Retina specialists have the privilege and responsibility of shaping this future for the visual health of current and future generations.